Formulary
Burosumab: Indications, Dosing, Side Effects and Interactions
Burosumab is a human monoclonal antibody that inhibits the activity of fibroblast growth factor 23, thereby increasing renal tubular reabsorption of phosphate...
MedNext Academy | 3 min read
Burosumab: Indications, Dosing, Side Effects and Interactions
Burosumab is a human monoclonal antibody that inhibits the activity of fibroblast growth factor 23, thereby increasing renal tubular reabsorption of phosphate...
Drug action
Burosumab is a human monoclonal antibody that inhibits the activity of fibroblast growth factor 23, thereby increasing renal tubular reabsorption of phosphate and increasing serum concentration of vitamin D.
Indications and dose
**X-linked hypophosphataemia (initiated by a specialist)**
- **Adult** (By Subcutaneous Injection): 1 mg/kg every 4 weeks (max. per dose 90 mg), dose may be administered 3 days either side of scheduled date if required, each dose should be rounded to the nearest 10 mg, dosing adjusted based on fasting serum-phosphate concentration-consult product literature.
**X-linked hypophosphataemia (initiated by a specialist) for burosumab**
- **Child 1-17 years** (By subcutaneous injection): 0.8 mg/kg every 2 weeks (max. per dose 90 mg), dose may be administered 3 days either side of scheduled date if required, each dose should be rounded to the nearest 10 mg, dosing adjusted based on fasting serum-phosphate concentration-consult product literature. Dose may be increased in steps of 0.4 mg/kg at intervals of at least 4 weeks up to a maximum of 2 mg/kg (max. per dose 90 mg).
Contraindications
Concurrent use of oral phosphate or vitamin D analogues-discontinue 1 week before initiation of burosumab
Side effects
Common or very common Back pain; constipation; dizziness; headaches; increased risk of infection; movement disorders; muscle spasms Frequency not known Hypersensitivity
Interactions
**Other interactions (1):**
- Caution should be exercised when combining burosumab with calcimimetic medicinal products (i.e.
Pregnancy
Manufacturer advises avoid- toxicity in animal studies.
Breast feeding
Manufacturer advises avoid-no information available.
Renal impairment
Manufacturer advises avoid in severe impairment- no information available.
Medicinal forms
Clinical governance
**Author:** MedNext Clinical Team. **Clinical reviewer:** Dr Shameer Deen, MBBS, MS, MRCS. **Sources:** BNF, Indian Pharmacopoeia, CIMS India. **Correction:** Report errors at support@mednext.academy.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- Growing visual cheat sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Subject HubPharmacology Hub
All pharmacology resources in one place.
Drug SchedulesIndian Drug Schedules
Schedule H, H1, X and G classifications.
FormularyBrowse all drugs
Search 1,850+ drug profiles.
Study Burosumab in the MedNext app
Challenge yourself with targeted pharmacology MCQs on this drug class. Every explanation links back to the chapter that teaches the concept.
Start drug challengeExplore the full formulary

